Discovery - University of Dundee - Online Publications

Library & Learning Centre

Inhibitors of the kinase IspE

Inhibitors of the kinase IspE: structure-activity relationships and co-crystal structure analysis

Research output: Contribution to journalArticle

View graph of relations

Authors

  • Anna K. H. Hirsch
  • Magnus S. Alphey
  • Susan Lauw
  • Michael Seet
  • Luzi Barandun
  • Wolfgang Eisenreich
  • Felix Rohdich
  • William N. Hunter
  • Adelbert Bacher
  • Francois Diederich

Research units

Info

Original languageEnglish
Pages2719-2730
Number of pages12
JournalOrganic and Biomolecular Chemistry
Journal publication date2008
Volume6
Issue15
DOIs
StatePublished

Abstract

Enzymes of the non-mevalonate pathway for isoprenoid biosynthesis are therapeutic targets for the treatment of important infectious diseases. Whereas this pathway is absent in humans, it is used by plants, many eubacteria and apicomplexan protozoa, including major human pathogens such as Plasmodium falciparum and Mycobacterium tuberculosis. Herein, we report on the design, preparation and biological evaluation of a new series of ligands for IspE protein, a kinase from this pathway. These inhibitors were developed for the inhibition of IspE from Escherichia coli, using structure-based design approaches. Structure-activity relationships (SARs) and a co-crystal structure of Aquifex aeolicus IspE bound to a representative inhibitor validate the proposed binding mode. The crystal structure shows that the ligand binds in the substrate-rather than the adenosine 5'-triphosphate (ATP)-binding pocket. As predicted, a cyclopropyl substituent occupies a small cavity not used by the substrate. The optimal volume occupancy of this cavity is explored in detail. In the co-crystal structure, a diphosphate anion binds to the Gly-rich loop, which normally accepts the triphosphate moiety of ATP. This structure provides useful insights for future structure-based developments of inhibitors for the parasite enzymes.

Documents

Library & Learning Centre

Contact | Accessibility | Policy